{
    "id": 16014,
    "cites": 33,
    "cited_by": 1,
    "reference": [
        "Abrantes-Metz, Rosa M., Christopher P. Adams and Albert D. Metz. Pharmaceutical Development Phases: A Duration Analysis. Journal of Pharmaceutical Finance, Economics and Policy 14(4):19-42, 2005. Abrantes-Metzz, Rosa M., Christopher P. Adams and Albert D. Metz. Determinants of Pharmaceutical Review, Success and Duration.",
        "Unpublished working paper, April 2008. Available from RAbrantesMetz @lecg.com.",
        "Adams, Christopher P. and Van V. Brantner. Estimating The Cost Of New Drug Development: Is It Really $802 Million? Health Affairs 25(2):420-428, March/April 2006.",
        "CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL MOLECULES? Page 43 NBER Working Paper w16014 Adams, Christopher P. and Van V. Brantner. Spending on New Drug Development. Health Economics 2009. Published online at www.interscience.wiley.com DOI: 10.1002/hec. 1454, 12 pp.",
        "Aitken, Murray L., Ernst R. Berndt and David M. Cutler. Prescription Drug Spending Trends in the U.S.: Looking Beyond the Turning Point. Health Affairs \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c Web Exclusive 28(1):W151-60, published online December 16, 2008; 10.1377.hlthaff.28.1.W138. Anderson, Kenneth N., Lois E. Anderson and Walter D. Glanze, eds. Mosby\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Medical, Nursing, & Allied Health Dictionary, 5th edition. St. Louis, MO: Mosby-Year Book, Inc.",
        "Berndt, Ernst R., Iain M. Cockburn and Karen A. Grepin. The Impact of Incremental Innovation on Biopharmaceuticals: Drug Utilization in Original and Supplemental Indications. Pharmacoeconomics 24 (Suppl. 2):69-86, 2006.",
        "Berndt, Ernst R., Rena N. Denoncourt and Anjli C. Warner. U.S. Markets for Vaccines: Characteristics, Case Studies and Controversies. Washington DC: AEI Press for the American Enterprise Institute, 2009. Berndt, Ernst R., Zvi Griliches and Joshua G. Rosett. Auding the Producer Price Index: Micro Evidence from Prescription Pharmaceutical Preparations.",
        "Bureau of Economic Analysis, National Economic Accounts. National Income and Products Accounts (NIPA) Interactive Table 1.1.9 Available at http://www.bea.gov/national/nipaweb/SelectTable.asp Accessed September, 2009.",
        "Cacciatore, Ken, Anant Padmanabhan and Ian Sanderson. Merck Entry Into Generic Biologics Validates our Thesis. New York: Cowen and Company, 2008.",
        "Calfee, John E. and Elizabeth DuPre. The Emerging Market Dynamics of Targeted Therapeutics. Health Affairs 25(5):1302-1308, September/October 2006. Danzon, Patricia, Sean Nicholson and Nuno Sousa Pereira. Productivity in Biotech-Pharmaceutical R&D: The Role of Experience and Alliances.",
        "CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL MOLECULES? Page 44 NBER Working Paper w16014 DiMasi, Joseph A. and Henry G. Grabowski. The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial Decision and Economics 28:469479, 2007.",
        "DiMasi, Joseph A., Henry G. Grabowski and John M. Vernon. R&D Costs and Returns by Therapeutic Category. Drug Information Journal 38(3):211223, 2004.",
        "DiMasi, Joseph A., Ronald G. Hansen and Henry G. Grabowski. The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics 22(1):151-185, 2003.",
        "Dranove, David and David Meltzer. Do Important Drugs Reach the Market Sooner? RAND Journal of Economics 25(3):402-422, 1994.",
        "Drug Facts and Comparisons 2008. St. Louis, MO: Wolters Kluwer Health, 2008.",
        "Gosse, Marilyn E. and Toben F. Nelson. Approval Times for Supplemental Indications for Recombinant Proteins. Nature Biotechnology 15(1):130134, 1997.",
        "Gosse, Marilyn E., Joseph A. DiMasi and Toben F. Nelson. Recombinant Protein and Therapeutic Monoclonal Antibody Drug Development in the United States: 1980-1994. Clinical Pharmacology and Therapeutics 60(6):608618.",
        "Grabowski, Henry G. Follow-on Biologics: Data Exclusivity and the Balance Between Innovation and Competition. Nature Reviews: Drug Discovery 7:479-488, June 2008. Published online doi:10.1038/nrd2532.",
        "Grabowski, Henry G., Iain M. Cockburn and Genia Long. The Market for Follow-On Biologics: How Will It Evolve? Health Affairs 25(5):12911301, September/October 2006.",
        "Grabowski, Henry G. and Margaret Kyle. Generic Competition and Market Exclusivity Period in Pharmaceuticals. Managerial Decision and Economics 28:491-502, 2007.",
        "Grabowski, Henry G., David B. Ridley and Kevin A. Schulman. Entry and Competition in Generic Biologics. Managerial Decision and Economics 28:439-451, 2007.",
        "CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL MOLECULES? Page 45 NBER Working Paper w16014 Hollingshead, Jim and Rob Jacoby. Avoiding No Man\u00c3\u00a2\u00e2\u0082\u00ac\u00cb\u009cs Land: Potential Unintended Consequences of Follow-On Biologics. San Francisco, CA: Deloitte Consulting LLP, March 2009. Available from jhollingshead@deloitte.com.",
        "Kotlikoff, Laurence J. Stimulating Innovation in the Biologics Industry: A Balanced Approach to Marketing Exclusivity. Teva USA Government Affairs, September 2008.",
        "Mishra, Neelkanth. Biosimilars: A Necessity, Not An Option. Mumbai, India: Credit Suisse, August 25, 2009. Available from Neelkanth.Mishra@credit-suisse.com.",
        "Physicians\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Desk Reference, 63rd edition. Montvale, New Jersey: Physicians\u00c3\u00a2\u00e2\u0082\u00ac\u00cb\u009c Desk Reference Inc., 2009.",
        "Reichert, Janice M. Monoclonal Antibody Successes in the Clinic. Nature Biotechnology 223(9):1073-1078, 2005.",
        "Reichert, Janice M. and Cherie Paquette. Clinical Development of Therapeutic Recombinant Proteins. BioTechniques 35(1):1-6, 2003.",
        "Trusheim, Mark R., Berndt Ernst R. and Douglas, Frank L. Stratified Medicine: Strategic and Economic Implications of Combining Drugs and Clinical Biomarkes. Nature Reviews Drug Discovery 6(4):287-293, 2007 United States Federal Trade Commission. Follow-on Biologic Drug Competition.",
        "Emerging Health Care Issues Report, June 2009. Available online from www.ftc.gov.",
        "United States Food and Drug Administration. Challenge and Opportunity on the Critical Path to New Medical Products. 2004. Available at http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf.",
        "United States Food and Drug Administration [2009a]. For Industry: Developing Products for Rare Diseases Conditions \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c Overview. Available online at http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesCond itions/Overview... Last accessed September 27, 2009.",
        "United States Food and Drug Administration [2009b]. For Consumers: Fast Track, Accelerated Approval and Priority Review. Available online at http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/Spe edingAccesstoI... Last accessed September 27, 2009.",
        "CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL MOLECULES? Page 46 NBER Working Paper w16014 WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system. Available online at http://www.whocc.no/atcddd/ ... Last accessed September 29, 2009."
    ]
}